The Laboratory of Molecular Neurooncology is located at the Department of Neurology of the University Hospital Zurich (Frauenklinikstrasse 26, CH-8091 Zurich). The Laboratory is led by Prof. Dr. M. Weller together with Prof. Dr. P. Roth, and Dr. M. Silginer (organisational chart).

Major research areas of the laboratory include cancer immunology, mechanisms of migration, invasion and angiogenesis, and resistance to therapy.

Major goals of our cancer immunology research include the characterization of immunological characteristics of glioma cells, in particular the putative tumor stem cells. We are also exploring transforming growth factor beta (TGF-beta)-mediated pathways and TGF-beta-targeting therapeutics. In the framework of clinical trials, we seek to develop translational research concepts regarding the immunogenicity of glioma cells. In this context, we aim at understanding molecular mechanisms and risks of vaccination concepts in glioma and the immunogenicity of glioma cells and tumor stem cells. In addition, we perform extensive studies on the primary and acquired resistance of glioma cells to radiotherapy and chemotherapy. In cooperation with the Department of Neurosurgery (Prof. Dr. L. Regli), we currently establish a tumor bank collecting tumor tissue for histology and molecular analyses as well as for the isolation and characterization of tumor-derived glioma stem cells.

Methods employed include fluorescence tomography for in vivo imaging in our preclinical models, flow cytometry and in the framework of cooperations two-photon microscopy and positron emission tomography.

In the area of clinical neurooncology, we founded, together with the partner institutions of neuroradiology, neurosurgery, nuclear medicine, neuropathology, radiation oncology, medical oncology and pediatric neurooncology, the Brain Tumor Center Zurich at the Cancer Center Zurich in January 2012.

In cooperation with the Centers of the German Glioma Network (, the German Consortium for Translational Cancer Research (DKTK) and the European Organization for Research and Treatment of Cancer (EORTC), we are involved in several clinical pathological molecular correlative projects looking at, e.g. prognostic and predictive value of molecular markers such as 1p 19q codeletion, MGMT promotor methylation and isocitrate dehydrogenase mutations in different glioma entities and long-time survival in glioblastoma.
The laboratory has been supported by the Brain Tumor Funder Collaborative, Swiss National Science Foundation, Oncosuisse, the Zurich Cancer League, the Wilhelm Sander-Foundation, the EMDO Foundation, the Hartmann-Müller Foundation and the Koetser Foundation and performs cooperative research projects with the pharmaceutical companies Abbvie (North Chicago, Illinois), Acceleron (Cambridge, Massachussets), Actelion (Baden, Switzerland), Bayer (Leverkusen/Berlin, Deutschland), Isarna (Regensburg, Germany), Merck Serono (Darmstadt, Germany), Novocure (Jersey Isle), OGD Parma, Piqur (Basel), Roche (Basel, Switzerland) and Tragara (San Diego, California).


Department of Neurology and Laboratory for Molecular Neuro-Oncology
University Hospital Zurich
Frauenklinikstrasse 26
8091 Zurich


Please click here to see the structural organisation chart.

You will find the list of group members on the following page.

Please click here to see the organisation chart of the laboratory teams.


Scientific projects

Selected scientific projects are listed in the table below. A complete overview and description of current and completed projects are listed on the website of the "Forschungsdatenbank" of the University of Zurich.

Current scientific projects

Funding source
​​Swiss National Science Foundation (SNF)
​P. Roth
​Defining novel targets for chimeric antigen receptor (CAR)-based immunotherapy against glioblastoma​03/2017 - 02/2020
​Swiss National Science Foundation (SNF) and Sinergia
​P. Roth
​Targeting HOTAIRM1 in glioblastoma
​12/2017 - 11/2020
Klinischer Forschungs-schwerpunkt (KFSP)
​P. Roth
M.G. Manz(Hematology)
​ImmunoCure​01/2019 - 12/2021

​Oncosuisse / Swiss Cancer League

​P. Roth
T. Weiss

lntegrins as targets for advanced chimeric antigen receptor (CAR) T cell treatment of glioblastoma

​04/2019 - 03/2022

​Oncosuisse / Swiss Cancer League​H.-G. Wirsching​Overcoming immune evasion of hypermutated glioblastoma​01/2020-12/2020
​OPO Foundation​H.-G. Wirsching

Digital Spatial Profiling to Map the Evolution of Intratumoral Immunologic Heterogeneity of Glioblastoma under Standard Chemoradiotherapy

01/2019 - 12/2019

Desirée and Niels Yde Foundation

H.-G. Wirsching

Evolution of the genomic-immunologic landscape of glioblastoma under chemoradiotherapy

01/2019 - 12/2021


Current clinical trials

Principal Investi­gator
Contact in Zurich
​EORTC 1608-BTG, Phase Ib

TGO2 in elderly newly diagnosed or adult relapsed patients with anaplastic astrocytoma or glioblastoma
​Prof. Dr. M. Weller,
​Newly diagnosed anaplastic astrocytoma or glioblastoma (>65 years)

Recurrent anaplastic astrocytoma or glioblastoma (>18 years)
​Prof. Dr. P. Roth​recruiting
CheckMate 548, phase III

Study of temozolomide plus radiation therapy with nivolumab or placebo, for newly diagnosed patients with glioblastoma
​Bristol-Myers Squibb,
Prof. Dr. P. Roth
​Newly diagnosed glioblastoma, methylated MGMT promotor​Prof. Dr. P. Roth
EORTC-1709-BTG, Phase III

Multicenter study of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma
​Prof. Dr. P. Roth​Newly diagnosed glioblastoma​Prof. Dr. P. Roth​recruiting
Gliomoon, phase I/II

A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF in patients with IDH wildtype WHO grade III /IV glioma at first relapse

​Dr. T. Weiss
​IDH wildtype WHO grade III /

IV glioma at first relapse

​Dr. T. Weiss​recruiting

Radiation versus observation following surgical resection of atypical meningioma

​EORTC, Prof. Dr. N. Andratschke​newly diagnosed atypical meningeoma (WHO grade II)​Prof. Dr. N. Andratschke​recruiting
CDI-CS-003, phase I/IIa

BAL101553 in patients with advanced solid tumors or recurrent glioblastoma
Prof. Dr. P. Roth  
​Recurrent glioblastoma​​Prof. Dr. P. Roth​recruiting
BGB-290-104, phase I/IIa

Multicenter study to assess the safety, tolerability
and efficacy of BGB-290 in combination with radiation
therapy and/or temozolomide in patients with newly diagnosed
or recurrent glioblastoma
Prof. Dr. M. Weller 
​Newly diagnosed glioblastoma, unmethylated MGMT promotor or recurrent glioblastoma
​Prof. Dr. M. Weller
Dr. K. Seystahl
Dr. H.G. Wirsching

Fitness to drive for Glioblastoma patients after standard therapy

​Dr. S. Hofer​Glioblastoma patients, without tumor progression after standard therapy or 6 months after diagnosis and without history of seizures within the last 12 months​Dr. S. Hofer​recruiting
PQR309-005, phase II

Open-label, non-randomized, two-stage study to evaluate the efficacy and safety of PQR309 in patients with progressive primary CNS lymphoms
​Prof. Dr. M. Weller,
​Recurrent primary CNS lymphoma
​Prof. Dr. M. Weller
Dr. D. Gramatzki
PCNSL01, phase II

Pembrolizumab for recurrent primary CNS lymphoma
​Prof. Dr. P. Roth
​Recurrent primary CNS lymphoma
​Prof. Dr. P. Roth


Completed PhD research projects

Completed projects of PhD students of our laboratory are listed below. Related publications can be found by the following link

SilginerManuelaIntegrin inhibition interferes with TGF-beta signaling in malignant glioma cells2010-012013-10
AhmadMushfikaHow stem-like are sphere cultures from long-term cancer cell lines?2010-082013-11
CodoPaulaGrowth and differentiation factor (GDF)-15, microRNA and the immunophenotype of glioblastoma2011-022014-09
StojcevaNinaTMZ resistance in glioblastoma2012-012015-06
ShanmugarajanKrishnanModulation of cerebral endothelial cell function by Glioma-Derived factors2012-102016-04
SchroederJudithThe Role of TGF-β Coreceptors in Glioblastoma2012-102015-09
ManganiDavideCo-inhibition of the TGF-β and VEGF pathways in glioblastoma2013-012017-06
PapaEleannaCrosstalk between the Met and TGF-β pathways in glioblastoma2013-012017-06
PapachristodoulouAlexandrosFocused ultrasound-mediated delivery of encapsulated MGMT antagonists for the treatment of temozolomide-resistant glioblastoma2013-012017-05
VenturaElisaExtracellular control of TGF-beta signaling in glioblastoma2013-012017-06
von AchenbachCarolineGrowth factor signalling in glioblastoma2015-022018-09
LohmannBirtheModulation of glioblastoma biology by type I interferons2015-012018-09
WeissTobiasCharacterisation and exploitation of the NKG2D system in glioblastoma2015-092019-04


Please follow the link to the detailed list of publications here.



We use cookies to make our website user-friendly, to continuously improve it and to analyze the traffic of our website. By continuing to browse the site, you are agreeing to our use of cookies. Further information can be found in our privacy policy.